Preclinical data targeting vascular endothelial growth factor in colorectal cancer
LM Ellis - Clinical colorectal cancer, 2004 - Elsevier
Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most
solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels
of VEGF in primary cancers are associated with increased microvessel density and poor
prognosis. These findings have led to preclinical studies evaluating the efficacy of anti-VEGF
therapy in inhibiting the growth of CRC in ectopic and orthotopic locations. In preclinical
models, numerous approaches to inhibit VEGF activity led to decreased tumor growth and …
solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels
of VEGF in primary cancers are associated with increased microvessel density and poor
prognosis. These findings have led to preclinical studies evaluating the efficacy of anti-VEGF
therapy in inhibiting the growth of CRC in ectopic and orthotopic locations. In preclinical
models, numerous approaches to inhibit VEGF activity led to decreased tumor growth and …
